Published in Xenobiotica on January 01, 1994
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 7.77
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest (2010) 5.39
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature (2013) 3.72
Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care (2011) 2.54
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med (2013) 1.91
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med (2015) 1.91
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
Molecular mechanism of action of metformin: old or new insights? Diabetologia (2013) 1.71
Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia (2011) 1.48
Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis. PLoS Negl Trop Dis (2017) 1.40
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes (2014) 1.29
Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila. PLoS One (2012) 1.19
GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. Diabetes (2011) 1.09
New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int (2014) 1.08
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget (2015) 1.06
Metformin and the gastrointestinal tract. Diabetologia (2016) 1.06
The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci (2013) 1.05
Clearance of the high intestinal (18)F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging (2010) 1.03
Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J (2015) 1.03
Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) (2013) 1.02
Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol (1994) 0.99
Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget (2014) 0.98
In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer (2012) 0.97
Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest (2014) 0.96
Metformin combined with aspirin significantly inhibit pancreatic cancer cell growth in vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and Bcl-2. Oncotarget (2015) 0.96
Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem (2014) 0.93
Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem (2014) 0.93
Metformin increases phagocytosis and acidifies lysosomal/endosomal compartments in AMPK-dependent manner in rat primary microglia. Naunyn Schmiedebergs Arch Pharmacol (2009) 0.92
Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care (2012) 0.92
Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol (2016) 0.92
Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One (2014) 0.91
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochem J (2015) 0.91
Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) (2013) 0.89
Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes. J Biol Chem (2013) 0.88
A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models. Oncotarget (2015) 0.87
Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology (2014) 0.87
Potential biomarker of metformin action. J Endocrinol (2014) 0.84
The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. J Cell Physiol (2014) 0.84
Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. Diabetes Care (2016) 0.83
Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget (2016) 0.82
Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr (2005) 0.82
Effect of Metformin on Viability, Morphology, and Ultrastructure of Mouse Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells and Balb/3T3 Embryonic Fibroblast Cell Line. Biomed Res Int (2015) 0.82
Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis (2014) 0.82
Metformin: historical overview. Diabetologia (2017) 0.81
Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes. Diabet Med (2015) 0.81
Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: an implication of synergy. Sci Rep (2015) 0.81
Update on the protective molecular pathways improving pancreatic beta-cell dysfunction. Mediators Inflamm (2013) 0.81
Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav Brain Res (2015) 0.80
Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn (2015) 0.80
Metformin (dimethyl-biguanide) induced DNA damage in mammalian cells. Genet Mol Biol (2011) 0.79
Metformin prevents the impairment of endothelium-dependent vascular relaxation induced by high glucose challenge in rabbit isolated perfused kidneys. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.79
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Metformin exaggerates phenylephrine-induced AMPK phosphorylation independent of CaMKKβ and attenuates contractile response in endothelium-denuded rat aorta. Biochem Pharmacol (2014) 0.79
In Vitro Anti-Echinococcal and Metabolic Effects of Metformin Involve Activation of AMP-Activated Protein Kinase in Larval Stages of Echinococcus granulosus. PLoS One (2015) 0.79
Metformin and Resveratrol Inhibited High Glucose-Induced Metabolic Memory of Endothelial Senescence through SIRT1/p300/p53/p21 Pathway. PLoS One (2015) 0.78
Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. Oncotarget (2015) 0.78
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia (2016) 0.78
Lipopolysaccharide-induced loss of cultured rat myenteric neurons - role of AMP-activated protein kinase. PLoS One (2014) 0.78
Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency. Am J Reprod Immunol (2014) 0.77
In Vitro and In Vivo Effects of Metformin on Osteopontin Expression in Mice Adipose-Derived Multipotent Stromal Cells and Adipose Tissue. J Diabetes Res (2015) 0.77
Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2. Cell Cycle (2016) 0.77
Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol (2014) 0.77
Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice. PLoS One (2016) 0.77
Effects of exercise training on mitochondrial function in patients with type 2 diabetes. World J Diabetes (2014) 0.76
Glucose supply and insulin demand dynamics of antidiabetic agents. J Diabetes Sci Technol (2010) 0.76
The desert gerbil Psammomys obesus as a model for metformin-sensitive nutritional type 2 diabetes to protect hepatocellular metabolic damage: Impact of mitochondrial redox state. PLoS One (2017) 0.75
Metformin as a cellular protector; a synoptic view of modern evidences. J Nephropharmacol (2015) 0.75
MATE2 Expression Is Associated with Cancer Cell Response to Metformin. PLoS One (2016) 0.75
Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus. J Clin Endocrinol Metab (2016) 0.75
Impact of metformin on reproductive tissues: an overview from gametogenesis to gestation. Ann Transl Med (2014) 0.75
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2. Endocr Relat Cancer (2016) 0.75
Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells. PLoS One (2016) 0.75
A Rapid and Convenient Method for in Vivo Fluorescent Imaging of Protoscolices of Echinococcus multilocularis. Korean J Parasitol (2016) 0.75
Metformin-clinical pharmacology in PCOs. J Med Life (2015) 0.75
Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state. Mol Metab (2017) 0.75
Influence of Plantago ovata husk (dietary fiber) on the bioavailability and other pharmacokinetic parameters of metformin in diabetic rabbits. BMC Complement Altern Med (2017) 0.75
Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer Cells. Balsaenggwa Saengsig (2017) 0.75
The alleviative effects of metformin for lipopolysaccharide-induced acute lung injury rat model and its underlying mechanism. Saudi Pharm J (2017) 0.75
Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature (1987) 10.21
Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia (1990) 2.75
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ (2000) 2.08
The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs (1999) 1.94
Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest (1997) 1.89
Subcellular distribution of metformin in rat liver. J Pharm Pharmacol (1991) 1.50
The structure of legumin, a storage protein of broad bean (Vicia faba) seed. Eur J Biochem (1970) 1.37
A comparative study of two serotypes of epidermolytic toxin from Staphylococcus aureus. Biochim Biophys Acta (1980) 1.28
Metformin and the intestine. Diabetologia (2008) 1.25
Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia (1981) 1.24
Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. Endocrinology (1993) 1.22
Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol (1990) 1.20
Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol (1988) 1.19
Insulin-like effect of pinitol. Br J Pharmacol (2000) 1.17
Improvement in glucose tolerance due to Momordica charantia (karela). Br Med J (Clin Res Ed) (1981) 1.16
A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf (1999) 1.15
Thyroid hormones, gonadal and adrenocortical steroids and the function of the islets of Langerhans. Endocr Rev (1984) 1.12
Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia (1980) 1.11
Hopelessness and violence among inner-city youths. Matern Child Health J (2001) 1.07
The isolation and characterisation of gas-cylinder membranes and alpha-granules from Anabaena flos-aquae D 124. Arch Mikrobiol (1969) 1.06
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. Int J Clin Pract (2010) 1.06
Hypoglycaemic effect of Momordica charantia extracts. Planta Med (1990) 1.05
The amino acid sequence of plastocyanin from Solanum tuberosum L. (potato). Biochem J (1974) 1.04
Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc Nutr Soc (1991) 1.04
Comparative tolerability profiles of oral antidiabetic agents. Drug Saf (1994) 1.03
Prevention of dexamethasone-induced insulin resistance by metformin. Biochem Pharmacol (1998) 1.02
Effect of metformin on glucose metabolism in mouse soleus muscle. Diabete Metab (1986) 1.02
The role of the serine protease active site in the mode of action of epidermolytic toxin of Staphylococcus aureus. FEMS Microbiol Lett (1991) 1.00
Glucose tolerance and plasma insulin of the rat in relation to the oestrous cycle and sex hormones. Horm Metab Res (1972) 1.00
Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab (2010) 0.98
Recombinant epidermolytic (exfoliative) toxin A of Staphylococcus aureus is not a superantigen. Med Microbiol Immunol (1992) 0.97
The UK Prospective Diabetes Study. Lancet (1998) 0.97
Role of ovarian hormones in the long-term control of glucose homeostasis. Interaction with insulin, glucagon and epinephrine. Horm Res (1980) 0.96
Epidermolytic toxin from Staphylococcus aureus binds to filaggrins. FEBS Lett (1986) 0.95
Epidermolytic toxin binds to components in the epidermis of a resistant species. Eur J Cell Biol (1989) 0.95
Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetes Res (1989) 0.95
Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumor. Biosci Rep (1986) 0.93
Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol (Copenh) (1986) 0.92
The rise and fall of troglitazone. Diabet Med (2000) 0.91
Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes (1983) 0.91
Evaluation of traditional plant treatments for diabetes: studies in streptozotocin diabetic mice. Acta Diabetol Lat (1989) 0.90
The electrophoretic mobility of peptides on paper at pH 1.9. Biochem J (1973) 0.90
The subunit structure of jack-bean urease. Biochem J (1969) 0.90
Valproic acid and fetal abnormality. Br Med J (Clin Res Ed) (1983) 0.90
Insulin and glucagon during pentobarbitone anaesthesia. Diabete Metab (1980) 0.89
Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab (2003) 0.89
RFLP for the human erb-A1 gene. Nucleic Acids Res (1987) 0.89
Role of ovarian hormones in the long-term control of glucose homeostasis, glycogen formation and gluconeogenesis. Ann Nutr Metab (1981) 0.89
Cloning and characterization of the gene for a methanol-utilising alcohol dehydrogenase from Bacillus stearothermophilus. Gene (1988) 0.88
Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice. Horm Metab Res (1981) 0.88
Hormonal control of glucose homeostasis during development and ageing in mice. Metabolism (1982) 0.88
Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes (1982) 0.88
Effect of ovarian hormones on glucose metabolism in mouse soleus muscle. Endocrinology (1985) 0.87
Stimulation of gastric inhibitory polypeptide release in ob/ob mice by oral administration of sugars and their analogues. J Nutr (1989) 0.87
Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol (1991) 0.86
Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab (2009) 0.86
Leptin prevents the fall in plasma osteocalcin during starvation in male mice. Biochem Biophys Res Commun (2002) 0.86
Dark-adapted sensitivity, rhodopsin content, and background adaptation in pcd/pcd mice. Invest Ophthalmol Vis Sci (1982) 0.86
The binding of epidermolytic toxin from Staphylococcus aureus to mouse epidermal tissue. Histochem J (1987) 0.86
Enzyme kinetics of cellulose hydrolysis. Biochem J (1989) 0.86
Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab (2014) 0.85
Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord (1998) 0.85
Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol (1984) 0.85
Treatment--metformin. Baillieres Clin Endocrinol Metab (1988) 0.85
The therapeutic use of lipoic acid in diabetes: a current perspective. Environ Toxicol Pharmacol (2001) 0.84
A circular-dichroism study of epidermolytic toxins A and B from Staphylococcus aureus. Biochem J (1982) 0.84
Effects of a transplantable insulinoma upon regulatory peptide concentrations in the gastrointestinal tract of the rat. Diabetologia (1986) 0.84
Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes. Br Med J (Clin Res Ed) (1983) 0.84
Melatonin inhibition of insulin secretion in the rat and mouse. Horm Res (1974) 0.84
Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice. Diabetes Obes Metab (2002) 0.84
Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes (1990) 0.83
Acute stimulation of glucose uptake by leptin in l6 muscle cells. Horm Metab Res (2002) 0.83
Purification and properties of tryptophan synthase from baker's yeast (Saccharomyces cerevisiae). Biochem J (1983) 0.83
Reduced hypothalamic neurotensin concentrations in the genetically obese diabetic (ob/ob) mouse: possible relationship to obesity. Metabolism (1991) 0.83
Defective regulation of glucokinase in rat pancreatic islet cell tumours. Acta Endocrinol (Copenh) (1987) 0.83
Anorectic effect of fenfluramine, cholecystokinin and neurotensin in genetically obese (ob/ob) mice. Comp Biochem Physiol A Comp Physiol (1986) 0.83
Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes. Biochem Pharmacol (1992) 0.82
Effects of transplantation and resection of a radiation-induced rat insulinoma on glucose homeostasis and the endocrine pancreas. Br J Cancer (1986) 0.82
Red blood cell catechol-o-methyl transferase, plasma catecholamines and renin in renal failure. Trans Am Soc Artif Intern Organs (1976) 0.82
Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice. Diabetologia (1983) 0.82
Hydrogen exchange kinetics and the mechanism of reaction B of yeast tryptophan synthase. Biochim Biophys Acta (1985) 0.81
Cerasee, a traditional treatment for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetes Res (1985) 0.81
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol (2003) 0.81
Central mu, delta, and kappa opioid binding sites, and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice. Life Sci (1989) 0.80
A new alcohol dehydrogenase, reactive towards methanol, from Bacillus stearothermophilus. Biochem J (1988) 0.80
Alloxan and ninhydrin inhibition of hexokinase from pancreatic islets and tumoural insulin-secreting cells. Pharmacol Toxicol (1990) 0.79
Delta opioid receptors mediate glucose uptake in skeletal muscles of lean and obese-diabetic (ob/ob) mice. Metabolism (2001) 0.79
Expression of GLUT2 in insulin-secreting AtT20 pituitary cells. J Mol Endocrinol (1998) 0.79
Insulin-releasing pituitary cells as a model for somatic cell gene therapy in diabetes mellitus. J Endocrinol (1994) 0.79
A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. Diabet Med (2007) 0.79
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J Endocrinol (2005) 0.79
Postreceptor effect of metformin on insulin action in mice. J Pharm Pharmacol (1985) 0.79
Knowledge, attitudes, technical competence, and blood glucose control of Type 1 diabetic patients during and after an education programme. Diabet Med (1990) 0.79
Activity requirements of epidermolytic toxin from Staphylococcus aureus studied by an in vitro assay. Toxicon (1990) 0.79
Beta-endorphin and corticotropin immunoreactivity and specific binding in the neuromuscular system of obese-diabetic mice. Neuroscience (1992) 0.79
Rotational co-culture of clonal β-cells with endothelial cells: effect of PPAR-γ agonism in vitro on insulin and VEGF secretion. Diabetes Obes Metab (2011) 0.78
Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycemic (ob/ob) mice. J Nutr (1991) 0.78
Blood glucose and plasma insulin levels during prolonged pentobarbitone anaesthesia in the rat. Endocrinol Exp (1975) 0.78